Alder BioPharmaceuticals (Alder BioPharmaceuticals) Intrinsic Value: Projected FCF : $0.00 (As of May. 06, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-06), Alder BioPharmaceuticals's Intrinsic Value: Projected FCF is $0.00. The stock price of Alder BioPharmaceuticals is $18.88. Therefore, Alder BioPharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Alder BioPharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:

ALDR's Price-to-Projected-FCF is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.39
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Alder BioPharmaceuticals Intrinsic Value: Projected FCF Historical Data

The historical data trend for Alder BioPharmaceuticals's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Intrinsic Value: Projected FCF Chart

Alder BioPharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Intrinsic Value: Projected FCF

Get a 7-Day Free Trial

-16.44

Alder BioPharmaceuticals Quarterly Data
	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19
Intrinsic Value: Projected FCF	Get a 7-Day Free Trial															-	-13.90	-16.44	-16.25	-15.61

Competitive Comparison of Alder BioPharmaceuticals's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Alder BioPharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alder BioPharmaceuticals's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alder BioPharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Alder BioPharmaceuticals's Price-to-Projected-FCF falls into.

Alder BioPharmaceuticals Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)

Add all the Free Cash Flow together and divide 6 will get Alder BioPharmaceuticals's Free Cash Flow(6 year avg) = $-150.37.

Alder BioPharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF	=	(Growth Multiple	*	Free Cash Flow (6 year avg)	+	Total Stockholders Equity (Jun19)	*	0.8)	/	Shares Outstanding (Diluted Average)
	=	(9.5203515959648	*	-150.36608	+	216.851	*	0.8)	/	83.480
	=	-15.07

Alder BioPharmaceuticals (NAS:ALDR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Alder BioPharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF	=	Share Price	/	Intrinsic Value: Projected FCF
	=	18.88	/	-15.070162310817
	=

Alder BioPharmaceuticals Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Intrinsic Value: Projected FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

11804 North Creek Parkway South, Bothell, WA, USA, 98011

Website

http://www.alderbio.com

Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

Executives

Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S	10 percent owner	9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno	director
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby	director, officer: President and CEO	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston	director	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green	director	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	director	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton	officer: Chief Business Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter	officer: Interim Chief Medical Officer	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620